Back to Results
First PageMeta Content
Healthcare reform in the United States / Presidency of Lyndon B. Johnson / Myelodysplastic syndrome / Syndromes / Erythropoietin / Medicare / Lenalidomide / Medicaid / National coverage determination / Medicine / Health / Federal assistance in the United States


2014: Volume 4, Number 4 A publication of the Centers for Medicare & Medicaid Services, Office of Information Products & Data Analytics Effect of Erythropoiesis-Stimulating Agent Policy Decisions on Off-Label Use in
Add to Reading List

Document Date: 2014-12-24 12:13:32

Open Document

File Size: 804,16 KB

Share Result on Facebook

City

College Station / Cary / Baltimore / /

Company

Neck Cancer Group / Hess / Statacorp / Medicare & Medicaid Research Review / GE / /

Currency

USD / /

/

Facility

University of Maryland / University of Maryland School / Yale University / /

IndustryTerm

pharmaceuticals / pharmaceutical / /

MarketIndex

MDS / Charlson Comorbidity / /

MedicalCondition

tumor / neoplasms / lymphocytic leukemia / cancer / HIV / lymphoma / multiple myeloma / disease / myelodysplastic syndromes / chronic / ESRD / Diseases / renal disease / end-stage renal disease / anemia / /

MedicalTreatment

red blood cell transfusions / blood transfusion / major surgery / chemotherapy / /

Organization

Greenebaum Cancer Center / University of Maryland School of Pharmacy / Yale School of Public Health / University of Maryland / U.S. Food and Drug Administration / Yale Cancer Center / Yale School of Medicine / CMS NCD / Yale University / office of Information Products & Data Analytics Effect of Erythropoiesis-Stimulating Agent Policy Decisions / Medicare / /

Person

David M. Bott / /

Position

Editor-in-Chief / Administrator / MP / Major / /

Product

zidovudine / /

ProvinceOrState

Maryland / /

Region

Midwest / /

Technology

alpha / diagnostic tests / chemotherapy / ESA / /

URL

http /

SocialTag